ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.96
0.71%
US Tech 100
20,762.73
1.73%
S&P 500
5,942.47
1.26%
US Dollar vs CAD
1.44457
0.00%
Bitcoin
97,640.17
-0.48%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vertex Pharmaceuticals Inc (VRTX)

  7. Vertex Pharmaceuticals Inc (VRTX) News

VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRTX
DateTimeSourceHeadlineSymbolCompany
12/23/20243:05PMBusiness WireVertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13NASDAQ:VRTXVertex Pharmaceuticals Inc
12/20/20242:51PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
12/20/20242:46PMBusiness WireVertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
12/20/20242:35PMBusiness WireVertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive VariantsNASDAQ:VRTXVertex Pharmaceuticals Inc
12/19/20245:00AMBusiness WireVertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral RadiculopathyNASDAQ:VRTXVertex Pharmaceuticals Inc
12/08/202411:52AMBusiness WireVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program UpdateNASDAQ:VRTXVertex Pharmaceuticals Inc
11/19/20243:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
11/15/20249:31AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
11/13/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
11/12/20243:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
11/08/20241:58PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
11/05/20243:11PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
11/05/20245:43AMIH Market NewsBoeing Ends Strike; Leadership Changes at Dollar Tree and Southwest; PLTR, HIMS, and ALAB Soar; MQ and LSCC DeclineNASDAQ:VRTXVertex Pharmaceuticals Inc
11/04/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
11/04/20243:01PMBusiness WireVertex Reports Third Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
10/29/20243:05PMBusiness WireVertex to Participate in Upcoming November Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
10/25/202412:00PMBusiness WireVertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week CongressNASDAQ:VRTXVertex Pharmaceuticals Inc
10/18/20247:00AMBusiness WireVertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual MeetingNASDAQ:VRTXVertex Pharmaceuticals Inc
10/17/20243:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
10/10/20243:05PMBusiness WireVertex to Announce Third Quarter 2024 Financial Results on November 4thNASDAQ:VRTXVertex Pharmaceuticals Inc
10/03/20243:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
10/02/20249:04AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
09/26/20248:00AMPR Newswire (Canada)Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
09/26/20248:00AMPR Newswire (Canada)Vertex annonce l'acceptation par Santé Canada de la soumission de drogue nouvelle pour l'association vanzacaftor/tézacaftor/deutivacaftor, un traitement d'association triple de nouvelle génération pour la fibrose kystiqueNASDAQ:VRTXVertex Pharmaceuticals Inc
09/26/20246:07AMBusiness WireVertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceNASDAQ:VRTXVertex Pharmaceuticals Inc
09/25/20242:51PMPR Newswire (Canada)Santé Canada accorde l'autorisation de mise sur le marché de la première thérapie d'édition génomique CRISPR/Cas9, CASGEVY® (exagamglogène autotemcel), pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusiNASDAQ:VRTXVertex Pharmaceuticals Inc
09/25/20242:50PMPR Newswire (Canada)Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
09/04/20243:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
09/04/20243:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/30/20243:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VRTX

Your Recent History

USOTC
TWOH
Two Hands (PK)
USOTC
GDVM
Global Developments (PK)
USOTC
AFFU
Affluence (PK)
NASDAQ
TNXP
Tonix Pharmaceuticals
NASDAQ
AVXL
Anavex Life Sciences
USOTC
SPZI
Spooz (PK)
USOTC
ZHUD
Zhuding (PK)
USOTC
FNMA
Fannie Mae (QB)
NYSE
IONQ
IonQ
USOTC
RDAR
Raadr (PK)
USOTC
BIEL
Bioelectronics (PK)
NASDAQ
TSLA
Tesla
USOTC
HMBL
HUMBL (PK)
NASDAQ
AMRN
Amarin
USOTC
RNVA
Rennova Health (CE)
USOTC
CGAC
Code Green Apparel (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads